Related Experiment Videos
Aspirin response and failure in cerebral infarction
C M Helgason1, K L Tortorice, S R Winkler
1Department of Neurology, University of Illinois, Chicago College of Medicine 60612.
Stroke
|March 1, 1993
Summary
Aspirin dose impacts platelet aggregation inhibition, crucial for stroke prevention. Individual responses vary, with some patients showing aspirin resistance even at higher doses.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Neurology
Background:
- Platelet aggregation inhibition is a key mechanism for aspirin's effectiveness in stroke prevention.
- Understanding individual responses to aspirin is vital for optimizing treatment.
Purpose of the Study:
- To evaluate the biological effect of aspirin by measuring platelet aggregation inhibition.
- To compare aspirin's effects in patients undergoing stroke prevention versus those with acute stroke.
Main Methods:
- Administered escalating doses of aspirin (325-1300 mg daily) to 113 patients for stroke prevention.
- Measured platelet aggregation inhibition in these patients and in 33 acute stroke patients pre-treatment.
Main Results:
- Complete platelet aggregation inhibition was achieved in most patients at doses up to 650 mg.
- Aspirin resistance (partial inhibition) was observed in some patients, even at 1300 mg.
- Similar patterns of inhibition and resistance were noted in acute stroke patients.
Conclusions:
- The precise relationship between platelet aggregation inhibition and stroke prevention efficacy requires further investigation.
- Individual variability in response to aspirin, including dose requirements and resistance, is significant.